Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases.
Read moreAnnual Revenue
$27.5B
Gilead's revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 36B. Over the last four quarters, Gilead's revenue has grown by 6%. Specifically, in Q1 2022's revenue was $6.6B; in Q4 2021, it was $7.2B; in Q3 2021, it was $7.4B; in Q2 2021, Gilead's revenue was $6.2B.